Key result
Chemotherapy and/or advanced breast cancer surgery were associated with higher odds of sickness absence during a two-year follow-up, with 13% of all women remaining absent at 24 months.
Why the study?
Does the type of cancer treatment (chemotherapy/advanced surgery) affect the occurrence and length of sickness absence in women following breast cancer surgery?
Cohort (n=497)
Does the type of cancer treatment (chemotherapy/advanced surgery) affect the occurrence and length of sickness absence in women following breast cancer surgery?
Answers are grounded in this paper and cite their sources.
Most women return to work within eight months after breast cancer surgery, but chemotherapy and advanced surgery increase the likelihood of prolonged sickness absence.
RATIONALE AND AIM: Most women of working ages with limited breast cancer (BC) have returned to work within the first year after diagnosis. However, little is known about what is happening during this year regarding sickness absence and return to work. Also, the knowledge is very limited about the occurrence of part-time sickness absence after BC diagnosis. Therefore, the aim of this study was to describe occurrence, extent and length of SA during a two-year follow-up after BC surgery and to analyse the association between being SA and type of cancer treatment. METHODS: In this prospective cohort study, 497 women responded to questionnaires about different aspects of sickness absence at six occasions during two years after primary BC surgery (at baseline and after 4, 8, 12, 18 and 24 months). Treatment information was obtained from the National breast cancer register. Multinomial logistic regression was used to calculate odds ratios (OR) for likelihood of being sickness absent more than once. RESULTS: Two-thirds of the women were sickness absent at baseline; this proportion decreased, especially during the first eight months. At 24 months, 13% were sickness absent. Of all women, 27% never reported sickness absence and 14% were sickness absent at most of the six survey times. At eight months, many had shifted from full- to part-time sickness absence. Women with chemotherapy and/or advanced BC surgery had higher ORs for being sickness absent at most of the follow-ups. CONCLUSIONS: Most women returned to work within the first eight months after BC surgery and of those sickness absent after that, most had been part-time sickness absent. Thus, it is important to differentiate between part- and full-time sickness absence in future studies. Special attention should be paid to the impact of chemotherapy and type of surgery on the likelihood of being sickness absent.
No takes yet. Share an insight, caveat, or question.
Petersson et al. (2017) conducted a cohort in Breast cancer (n=497). Chemotherapy and/or advanced breast cancer surgery was evaluated on Likelihood of being sickness absent more than once. Chemotherapy and/or advanced breast cancer surgery were associated with higher odds of sickness absence during a two-year follow-up, with 13% of all women remaining absent at 24 months.
Synapse has enriched 10 related papers. Consider them for comparative context: